SI-BONE Stock (NASDAQ:SIBN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$15.37

52W Range

$11.48 - $21.89

50D Avg

$13.87

200D Avg

$15.73

Market Cap

$671.45M

Avg Vol (3M)

$693.05K

Beta

0.70

Div Yield

-

SIBN Company Profile


SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

349

IPO Date

Oct 17, 2018

Website

SIBN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Non-US$2.09M$2.26M$1.97M$1.80M$1.81M$2.07M$1.88M$1.89M$1.96M$1.67M$1.47M$1.45M
UNITED STATES$31.21M$30.45M$29.99M$24.63M$23.77M$20.37M$23.35M$20.39M$20.23M$18.77M$20.68M$18.92M

Fiscal year ends in Dec 25 | Currency in USD

SIBN Financial Summary


Dec 25Dec 24Dec 23
Revenue$200.93M$167.18M$138.89M
Operating Income$-22.33M$-35.25M$-46.93M
Net Income$-18.91M$-30.91M$-43.34M
EBITDA$-22.33M$-23.09M$-34.45M
Basic EPS$-0.44$-0.75$-1.13
Diluted EPS$-0.44$-0.75$-1.13

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 12, 26 | 12:00 AM
Q4 25Feb 23, 26 | 4:30 PM
Q3 25Nov 10, 25 | 4:30 PM

Peer Comparison


TickerCompany
AIRSAirSculpt Technologies, Inc.
CLPTClearPoint Neuro, Inc.
PACBPacific Biosciences of California, Inc.
AVXLAnavex Life Sciences Corp.
AQSTAquestive Therapeutics, Inc.
AVNSAvanos Medical, Inc.
INNVInnovAge Holding Corp.
VREXVarex Imaging Corporation
BFLYButterfly Network, Inc.
OFIXOrthofix Medical Inc.